Aldeyra Therapeutics, Inc.
ALDX Real Time Price USDRecent trades of ALDX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ALDX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Toxic aldehyde related diseases and treatment Oct. 29, 2024
-
Patent Title: Process for preparation of aldehyde scavenger and intermediates Sep. 24, 2024
-
Patent Title: Compositions and methods for the treatment of macular degeneration Sep. 24, 2024
-
Patent Title: Pharmaceutical formulations and uses thereof Aug. 20, 2024
-
Patent Title: Polymorphic compounds and uses thereof Jul. 09, 2024
-
Patent Title: Polymorphic compounds and uses thereof Jun. 11, 2024
-
Patent Title: Ophthalmic formulations of methotrexate Jun. 11, 2024
-
Patent Title: Ophthalmic formulations of methotrexate Jun. 11, 2024
-
Patent Title: Methotrexate treatment methods Feb. 27, 2024
-
Patent Title: Deuterated compounds and uses thereof Dec. 19, 2023
-
Patent Title: Ophthalmic formulations and uses thereof Oct. 17, 2023
-
Patent Title: Toxic aldehyde related diseases and treatment Oct. 03, 2023
-
Patent Title: Compositions and methods of treating retinal disease Aug. 15, 2023
-
Patent Title: Toxic aldehyde related diseases and treatment Jul. 18, 2023
-
Patent Title: Treatment of inflammatory disorders Feb. 21, 2023
-
Patent Title: Deuterated compounds and uses thereof Oct. 04, 2022
-
Patent Title: Polymorphic compounds and uses thereof Apr. 26, 2022
-
Patent Title: Formulations for treatment of dry eye disease Dec. 14, 2021
-
Patent Title: Combination treatment of ocular inflammatory disorders and diseases Sep. 28, 2021
-
Patent Title: Deuterated compounds and uses thereof Jun. 29, 2021
-
Patent Title: Treatment of inflammatory disorders Jun. 22, 2021
-
Patent Title: Toxic aldehyde related diseases and treatment May. 18, 2021
-
Patent Title: Compositions and methods of treating retinal disease Feb. 09, 2021
-
Patent Title: Toxic aldehyde related diseases and treatment Mar. 17, 2020
-
Patent Title: Deuterated compounds and uses thereof Feb. 04, 2020
-
Patent Title: Toxic aldehyde related diseases and treatment Jan. 28, 2020
-
Patent Title: Treatment of allergic eye conditions with cyclodextrins Oct. 01, 2019
-
Patent Title: Polymorphic compounds and uses thereof Sep. 17, 2019
-
Patent Title: Toxic aldehyde related diseases and treatment Feb. 26, 2019
-
Patent Title: Compositions and methods of treating retinal disease Feb. 12, 2019
-
Patent Title: Traps in the treatment of macular degeneration Oct. 30, 2018
-
Patent Title: Compositions and methods of treating retinal disease Feb. 20, 2018
-
Patent Title: Compositions and methods for the treatment of macular degeneration Nov. 14, 2017
-
Patent Title: Toxic aldehyde related diseases and treatment Jun. 27, 2017
-
Patent Title: Compositions and methods of treating retinal disease May. 16, 2017
-
Patent Title: Peri-carbinols Mar. 28, 2017
-
Patent Title: Compositions and methods of treating retinal disease Jun. 14, 2016
-
Patent Title: Compositions and methods of treating retinal disease Feb. 23, 2016
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ALDX in WallStreetBets Daily Discussion
Recent insights relating to ALDX
Recent picks made for ALDX stock on CNBC
ETFs with the largest estimated holdings in ALDX
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ALDX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.